ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,381.35
0.33%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,347.28
0.02%
Brent Oil
84.075
0.15%
Bitcoin
62,792.92
-0.41%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XOMA Corporation (XOMAO)

  7. XOMA Corporation (XOMAO) News

XOMA (XOMAO)

XOMA Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMAO
DateTimeSourceHeadlineSymbolCompany
09/05/202412:30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAOXOMA Corporation
30/04/202412:30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAOXOMA Corporation
25/04/202412:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAOXOMA Corporation
03/04/202414:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAOXOMA Corporation
21/03/202411:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAOXOMA Corporation
19/03/202420:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAOXOMA Corporation
08/03/202412:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAOXOMA Corporation
28/02/202412:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAOXOMA Corporation
16/02/202413:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAOXOMA Corporation
18/01/202413:30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAOXOMA Corporation
11/01/202421:05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAOXOMA Corporation
08/01/202412:30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAOXOMA Corporation
02/01/202412:30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAOXOMA Corporation
20/12/202312:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAOXOMA Corporation
19/12/202312:30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAOXOMA Corporation
07/11/202312:30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAOXOMA Corporation
31/10/202311:30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAOXOMA Corporation
25/09/202312:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAOXOMA Corporation
06/09/202312:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAOXOMA Corporation
08/08/202312:30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAOXOMA Corporation
23/06/202323:14GlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAOXOMA Corporation
22/06/202312:30GlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAOXOMA Corporation
20/06/202312:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAOXOMA Corporation
25/05/202321:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
22/05/202321:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
22/05/202321:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
19/05/202322:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
19/05/202321:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
19/05/202321:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
19/05/202321:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAOXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMAO

Your Recent History

LSE
ITM
Itm Power
LSE
TYM
Tertiary Minerals
LSE
AGL
Angle
LSE
PEN
Pennant
NYSE
SPCE
Virgin Galactic
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved